Dr. Bonar's research focuses primarily on improving health outcomes for patients dealing with severe nausea, particularly in palliative care, and finding better treatment options for inflammatory diseases like rheumatoid arthritis. She also investigates the use of specialized technology that helps individuals with speech challenges communicate more effectively. Additionally, she studies the biological mechanisms involved in bone healing and growth, aiming to enhance recovery for patients with bone disorders. Furthermore, her work includes developing new medications that specifically target inflammatory pathways to reduce symptoms for patients with chronic inflammatory conditions.
Key findings
In a 2023 study, olanzapine reduced the need for nausea medication doses from an average of 1.6 to 0.6 among 78 palliative care patients, improving appetite for many.
Research on external fixators for severe ankle fractures showed that all 48 patients healed well, with an average ankle score of 67 points after two years and only two minor infections.
In a 2005 study, six out of 21 tested compounds effectively lowered IL-8 production in rheumatoid arthritis patients, reducing inflammation.
The use of the new drug SC-514 was shown to significantly decrease NF-kappa B-driven gene activity in rheumatoid arthritis cells, pointing to a promising treatment option.
In developing PH-797804, researchers found it to be a strong and selective inhibitor that could improve treatments for inflammatory diseases.
Frequently asked questions
Does Dr. Bonar study speech difficulties?
Yes, she investigates how to improve communication through technology for individuals with speech challenges.
What treatments has Dr. Bonar researched for nausea?
She has studied the effectiveness of olanzapine, finding it reduces nausea medication needs for palliative care patients.
Is Dr. Bonar's work relevant to arthritis patients?
Yes, her research focuses on developing new treatments for rheumatoid arthritis and other inflammatory diseases.
How does Dr. Bonar help patients with bone disorders?
Her studies on bone cell signaling mechanisms aim to enhance healing and treatment options for patients with bone-related issues.
What innovations has Dr. Bonar contributed to fracture treatment?
She has developed new techniques and devices, such as the articulated external fixator, which improves outcomes for ankle fractures.
Publications in plain English
Canadian manufacturer and technician perspectives on the design and use of augmentative and alternative communication technology.
2024
Disability and rehabilitation. Assistive technology
Plain English This study looked at the views of manufacturers and technicians who create and support communication devices for people with speech difficulties. Researchers gathered a group of these professionals in Canada and found that they face challenges in making devices user-friendly while also needing more financial support to help users effectively. They believe that better funding and more access to these devices for users could improve communication outcomes significantly for those in need.
Who this helps: This helps patients with speech difficulties and the professionals supporting them.
Olanzapine for Non-Chemotherapy Related Nausea and Emesis in Patients with a Palliative Care Consult.
2023
Journal of pain and symptom management
Bonar S, Schneider HL, Cook K, Samala RV, Poole MFF
Plain English This study looked at how well olanzapine, a medication usually used for treating mental health issues, can help relieve nausea and vomiting in patients receiving palliative care—not those undergoing chemotherapy. Out of 78 patients, those who took olanzapine required fewer doses of other nausea medications (down from an average of 1.6 to 0.6 doses), and many showed improved appetite. Most importantly, using olanzapine also helped reduce the cost of nausea medication and was safely prescribed to 69% of patients discharged from the hospital.
Who this helps: This benefits patients in palliative care who struggle with nausea and vomiting.
Postnatal ablation of osteoblast Smad4 enhances proliferative responses to canonical Wnt signaling through interactions with β-catenin.
2013
Journal of cell science
Salazar VS, Zarkadis N, Huang L, Watkins M, Kading J +4 more
Plain English This study looked at the role of a protein called Smad4 in bone-building cells, specifically how it interacts with Wnt signaling to control cell growth and development. Researchers found that when Smad4 is removed from these cells, the rate of cell division increases significantly, while the process of maturation slows down. Specifically, removing Smad4 led to more rapid cell division on the bone surface, but reduced the ability of these cells to produce a mineralized bone matrix. This matters because understanding how to control cell growth and differentiation can help improve bone healing and treatment for bone-related diseases.
Who this helps: This helps patients with bone disorders and fractures by providing insights that could lead to better treatments.
Plain English This study focused on developing new drugs that specifically target a protein called p38 kinase, which is involved in inflammation. Researchers created a series of compounds and found that two of them, labeled as compounds 2 and 3, were especially effective at reducing inflammation in both short-term and long-term experiments. These findings are important because they could lead to new treatments for inflammatory conditions, improving patient care.
Who this helps: Patients with inflammatory diseases.
Plain English Researchers developed a new drug called PH-797804, which specifically targets a protein called p38 MAP kinase involved in inflammation. They tested its effectiveness and found that it is a strong and precise inhibitor, showing promise for treating inflammatory diseases. This discovery is important because it could lead to better treatments for conditions like arthritis and other inflammatory disorders.
Who this helps: Patients suffering from inflammatory diseases.
Inhibition of IKK-2 by 2-[(aminocarbonyl)amino]-5-acetylenyl-3-thiophenecarboxamides.
2005
Bioorganic & medicinal chemistry letters
Bonafoux D, Bonar S, Christine L, Clare M, Donnelly A +13 more
Plain English This research looked at a new group of compounds designed to block a specific enzyme called IKK-2, which is involved in inflammation. Out of 21 different compounds tested, six were found to significantly reduce the production of an inflammatory substance called IL-8 in cells from patients with rheumatoid arthritis. This matters because lowering IL-8 can help reduce inflammation and improve symptoms for people with this condition.
Who this helps: This benefits patients with rheumatoid arthritis.
A selective IKK-2 inhibitor blocks NF-kappa B-dependent gene expression in interleukin-1 beta-stimulated synovial fibroblasts.
2003
The Journal of biological chemistry
Kishore N, Sommers C, Mathialagan S, Guzova J, Yao M +10 more
Plain English This study looked at a new drug called SC-514, which targets a specific enzyme (IKK-2) involved in the inflammation process, particularly in diseases like arthritis. Researchers found that SC-514 effectively blocks the gene activity driven by a protein called NF-kappa B in cells from patients with rheumatoid arthritis when stimulated by interleukin-1 beta. Specifically, it reduced this gene activity in a measurable way, showing that lower doses of the drug led to decreased inflammatory responses.
Who this helps: This research benefits patients with inflammatory diseases like rheumatoid arthritis by providing a potential new treatment option.
A simple technique for insertion of distal screws into interlocking nails.
1995
Journal of orthopaedic trauma
Kelley SS, Bonar S, Hussamy OD, Morrison JA
Plain English This study explored a new method for inserting screws into interlocking nails for bone fractures, focusing on a specific technique called the "third point in space." The researchers found that this method worked well in over 30 cases and is simple, reliable, and cost-effective, eliminating the need for expensive tools. This matters because it can make surgeries easier and safer for patients with bone fractures.
Who this helps: Patients with femoral and tibial fractures.
Use of an articulated external fixator for fractures of the tibial plafond.
1995
The Journal of bone and joint surgery. American volume
Marsh JL, Bonar S, Nepola JV, Decoster TA, Hurwitz SR
Plain English Researchers studied the treatment of severe ankle fractures (tibial plafond fractures) in 48 patients using a special external device called an articulated external fixator. They found that all fractures healed, and infections were rare, with only two cases of minor infections that were successfully treated. This approach helped minimize complications and provided good outcomes, with an average ankle score of 67 points after two years.
Who this helps: This benefits patients with severe ankle fractures seeking effective treatment options.
Recurrent cholangitis secondary to oriental cholangiohepatitis.
1989
Journal of clinical gastroenterology
Bonar S, Burrell M, West B, Cahow CE
Plain English This study focused on a Korean woman who repeatedly experienced cholangitis, a liver infection, due to a condition called Oriental cholangiohepatitis, which has become more common in the U.S. as more people from East Asia immigrate. The symptoms are similar to those caused by gallstones, but the causes and treatments are very different. Recognizing this condition is important, especially in patients with a history of certain parasitic infections or who have lived in areas where the disease is common.
Who this helps: This helps doctors diagnose and treat patients with liver infections accurately.